Biohaven Ltd. (NYSE:BHVN) Shares Bought by Cwm LLC

Cwm LLC grew its position in shares of Biohaven Ltd. (NYSE:BHVN) by 87.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,679 shares of the company’s stock after purchasing an additional 6,400 shares during the period. Cwm LLC’s holdings in Biohaven were worth $329,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of Biohaven in the fourth quarter worth approximately $1,384,000. HighTower Advisors LLC boosted its position in shares of Biohaven by 6.1% in the fourth quarter. HighTower Advisors LLC now owns 5,870 shares of the company’s stock worth $219,000 after acquiring an additional 335 shares during the last quarter. Xponance Inc. boosted its position in shares of Biohaven by 25.9% in the fourth quarter. Xponance Inc. now owns 6,148 shares of the company’s stock worth $230,000 after acquiring an additional 1,263 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of Biohaven by 31.6% in the fourth quarter. Teacher Retirement System of Texas now owns 23,320 shares of the company’s stock worth $871,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Biohaven in the fourth quarter worth approximately $355,000. 88.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BHVN shares. William Blair raised shares of Biohaven to a “strong-buy” rating in a research report on Thursday, April 24th. Cantor Fitzgerald raised shares of Biohaven to a “strong-buy” rating in a research report on Tuesday, May 13th. Robert W. Baird decreased their target price on shares of Biohaven from $60.00 to $57.00 and set an “outperform” rating on the stock in a research report on Monday, April 28th. JPMorgan Chase & Co. decreased their target price on shares of Biohaven from $68.00 to $55.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 18th. Finally, Royal Bank Of Canada cut shares of Biohaven from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $54.00 to $21.00 in a research report on Monday, May 19th. One investment analyst has rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Biohaven presently has a consensus rating of “Buy” and an average price target of $58.46.

Biohaven Stock Performance

NYSE BHVN opened at $13.50 on Friday. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -1.44 and a beta of 0.91. The company’s 50 day moving average price is $14.85 and its 200 day moving average price is $24.39. Biohaven Ltd. has a one year low of $13.04 and a one year high of $55.70.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, May 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.50). Sell-side analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.